Pharmaceutical company GlaxoSmithKline recently gained approval for two cancer drugs --- Mekinist and Tafinlar --- but the Food and Drug Administration recently announced that a combination treatment consisting of these two drugs has been given priority review status. In the following video from The Motley Fool's show Market Checkup, health-care analysts David Williamson and Max Macaluso discuss the details behind this news and the potential impact on GlaxoSmithKline's business.
Cash in on big pharma
One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
The relevant video segment can be found between 3:25-6:01.
The article A New Combination Treatment for Big Pharma GlaxoSmithKline? originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.